FDA updates Gilead's label for CAR-T Tecartus with new boxed warning for secondary cancer
The FDA on Monday pulled but then updated and published a new letter to Gilead advising that its CAR-T drug Tecartus does need a boxed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
